公开(公告)号：US20130012708A1

公开(公告)日：2013-01-10

申请号：US13613195

申请日：2012-09-13

申请人： Shingo Owada ,  Shunsuke Iwamoto ,  Kazufumi Yanagihara ,  Katsuaki Miyaji ,  Takanori Nakamura ,  Norihisa Ishiwata ,  Yutaka Hirokawa

发明人： Shingo Owada ,  Shunsuke Iwamoto ,  Kazufumi Yanagihara ,  Katsuaki Miyaji ,  Takanori Nakamura ,  Norihisa Ishiwata ,  Yutaka Hirokawa

IPC分类号： C07D409/12 ,  C07D333/32 ,  C07D409/14 ,  C07D417/12 ,  C07D413/12 ,  C07D231/18 ,  C07D403/12

CPC分类号： C07D417/12 ,  C07D231/18 ,  C07D295/192 ,  C07D333/32 ,  C07D333/38 ,  C07D403/12 ,  C07D409/12

摘要： A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13, SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

摘要翻译： 由式（1）表示的化合物：其中A是氮原子或CR 4，B是氧原子，硫原子或NR 9（条件是当A是氮原子时，B不是NH），R1是C2 -14芳基，L1为键，CR10R11，氧原子，硫原子或NR12，X为OR13，SR13或NR14NR15，R2为氢原子，甲酰基，C1-10烷基等， L2是键或类似物，L3是键，CR17R18，氧原子，硫原子或NR19，L4是键，CR20R21，氧原子，硫原子或NR22，Y是氧原子，硫 原子或NR 23，并且R 3是该化合物或其溶剂合物的C2-14芳基，互变异构体，前药或药学上可接受的盐。

公开(公告)号：US08318796B2

公开(公告)日：2012-11-27

申请号：US12492435

申请日：2009-06-26

申请人： Shingo Owada ,  Shunsuke Iwamoto ,  Kazufumi Yanagihara ,  Katsuaki Miyaji ,  Takanori Nakamura ,  Norihisa Ishiwata ,  Yutaka Hirokawa

发明人： Shingo Owada ,  Shunsuke Iwamoto ,  Kazufumi Yanagihara ,  Katsuaki Miyaji ,  Takanori Nakamura ,  Norihisa Ishiwata ,  Yutaka Hirokawa

IPC分类号： A61K31/38 ,  C07D333/12

CPC分类号： C07D417/12 ,  C07D231/18 ,  C07D295/192 ,  C07D333/32 ,  C07D333/38 ,  C07D403/12 ,  C07D409/12

摘要： A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13, SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

摘要翻译： 由式（1）表示的化合物：其中A是氮原子或CR 4，B是氧原子，硫原子或NR 9（条件是当A是氮原子时，B不是NH），R1是C2 -14芳基，L1为键，CR10R11，氧原子，硫原子或NR12，X为OR13，SR13或NR14NR15，R2为氢原子，甲酰基，C1-10烷基等， L2是键或类似物，L3是键，CR17R18，氧原子，硫原子或NR19，L4是键，CR20R21，氧原子，硫原子或NR22，Y是氧原子，硫 原子或NR 23，并且R 3是该化合物或其溶剂合物的C2-14芳基，互变异构体，前药或药学上可接受的盐。

公开(公告)号：US20110077290A1

公开(公告)日：2011-03-31

申请号：US12492435

申请日：2009-06-26

申请人： Shingo OWADA ,  Shunsuke Iwamoto ,  Kazufumi Yanagihara ,  Katsuaki Miyaji ,  Takanori Nakamura ,  Norihisa Ishiwata ,  Yutaka Hirokawa

发明人： Shingo OWADA ,  Shunsuke Iwamoto ,  Kazufumi Yanagihara ,  Katsuaki Miyaji ,  Takanori Nakamura ,  Norihisa Ishiwata ,  Yutaka Hirokawa

IPC分类号： A61K31/381 ,  C07D333/32 ,  A61P7/04

CPC分类号： C07D417/12 ,  C07D231/18 ,  C07D295/192 ,  C07D333/32 ,  C07D333/38 ,  C07D403/12 ,  C07D409/12

摘要： A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13, SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

摘要翻译： 由式（1）表示的化合物：其中A是氮原子或CR 4，B是氧原子，硫原子或NR 9（条件是当A是氮原子时，B不是NH），R1是C2 -14芳基，L1为键，CR10R11，氧原子，硫原子或NR12，X为OR13，SR13或NR14NR15，R2为氢原子，甲酰基，C1-10烷基等， L2是键或类似物，L3是键，CR17R18，氧原子，硫原子或NR19，L4是键，CR20R21，氧原子，硫原子或NR22，Y是氧原子，硫 原子或NR 23，并且R 3是该化合物或其溶剂合物的C2-14芳基，互变异构体，前药或药学上可接受的盐。

公开(公告)号：US07576115B2

公开(公告)日：2009-08-18

申请号：US11837659

申请日：2007-08-13

申请人： Shingo Owada ,  Shunsuke Iwamoto ,  Kazufumi Yanagihara ,  Katsuaki Miyaji ,  Takanori Nakamura ,  Norihisa Ishiwata ,  Yutaka Hirokawa

发明人： Shingo Owada ,  Shunsuke Iwamoto ,  Kazufumi Yanagihara ,  Katsuaki Miyaji ,  Takanori Nakamura ,  Norihisa Ishiwata ,  Yutaka Hirokawa

IPC分类号： A61K31/415 ,  C07D231/10

CPC分类号： C07D417/12 ,  C07D231/18 ,  C07D295/192 ,  C07D333/32 ,  C07D333/38 ,  C07D403/12 ,  C07D409/12

摘要： A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13, SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or is pharmaceutically acceptable salt of the compound or a solvate thereof.

摘要翻译： 由式（1）表示的化合物：其中A是氮原子或CR 4，B是氧原子，硫原子或NR 9（条件是当A是氮原子时，B不是NH），R1是C2 -14芳基，L1是键，CR10R11，氧原子，硫原子或NR12，X是OR13，SR13或NR14NR15，R2是氢原子，甲酰基，C1-10烷基等， L2是键或类似物，L3是键，CR17R18，氧原子，硫原子或NR19，L4是键，CR20R21，氧原子，硫原子或NR22，Y是氧原子，硫原子 原子或NR 23，并且R 3是C 12-14芳基，互变异构体，前药或化合物或其溶剂合物的药学上可接受的盐。

公开(公告)号：US20060094694A1

公开(公告)日：2006-05-04

申请号：US11294609

申请日：2005-12-06

申请人： Shingo Owada ,  Shunsuke Iwamoto ,  Kazufumi Yanagihara ,  Katsuaki Miyaji ,  Takanori Nakamura ,  Norihisa Ishiwata ,  Yutaka Hirokawa

发明人： Shingo Owada ,  Shunsuke Iwamoto ,  Kazufumi Yanagihara ,  Katsuaki Miyaji ,  Takanori Nakamura ,  Norihisa Ishiwata ,  Yutaka Hirokawa

IPC分类号： A61K31/675 ,  C07D261/12 ,  C07D231/08 ,  A61K31/42 ,  A61K31/4152

CPC分类号： C07D417/12 ,  C07D231/18 ,  C07D295/192 ,  C07D333/32 ,  C07D333/38 ,  C07D403/12 ,  C07D409/12

摘要： A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13 SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

摘要翻译： 由式（1）表示的化合物：其中A是氮原子或CR 4，B是氧原子，硫原子或NR 9（条件是当 A是氮原子，B不是NH），R 1是C 2-14芳基，L 1是一个键， 氧原子，硫原子或NR 12，X是OR 13， 或者NR 14是NR 15，R 2是氢原子，甲酰基，C 1 -C 6烷基， 1-10个烷基等，L 2是一个键或类似物，L 3是一个键，CR 17 R 18是氧原子，硫原子或NR 19，L 4是键，CR 20 R 21，氧原子，硫原子或NR 22，Y是氧原子，硫原子或NR 23，和 R 3是C 2-14芳基，该化合物的互变异构体，前药或药学上可接受的盐或其溶剂化物。

公开(公告)号：US07351841B2

公开(公告)日：2008-04-01

申请号：US11294609

申请日：2005-12-06

申请人： Shingo Owada ,  Shunsuke Iwamoto ,  Kazufumi Yanagihara ,  Katsuaki Miyaji ,  Takanori Nakamura ,  Norihisa Ishiwata ,  Yutaka Hirokawa

发明人： Shingo Owada ,  Shunsuke Iwamoto ,  Kazufumi Yanagihara ,  Katsuaki Miyaji ,  Takanori Nakamura ,  Norihisa Ishiwata ,  Yutaka Hirokawa

IPC分类号： C07D333/12 ,  C07D333/16 ,  C07D333/18 ,  C07D333/20 ,  C07D333/32 ,  C07D333/34 ,  A61K31/381

CPC分类号： C07D417/12 ,  C07D231/18 ,  C07D295/192 ,  C07D333/32 ,  C07D333/38 ,  C07D403/12 ,  C07D409/12

摘要： A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13 SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

摘要翻译： 由式（1）表示的化合物：其中A是氮原子或CR 4，B是氧原子，硫原子或NR 9（条件是当 A是氮原子，B不是NH），R 1是C 2-14芳基，L 1是一个键， 氧原子，硫原子或NR 12，X是OR 13， 或者NR 14是NR 15，R 2是氢原子，甲酰基，C 1 -C 6烷基， 1-10个烷基等，L 2是一个键或类似物，L 3是一个键，CR 17 R 18是氧原子，硫原子或NR 19，L 4是键，CR 20 R 21，氧原子，硫原子或NR 22，Y是氧原子，硫原子或NR 23，和 R 3是C 2-14芳基，该化合物的互变异构体，前药或药学上可接受的盐或其溶剂化物。

公开(公告)号：US20090198060A1

公开(公告)日：2009-08-06

申请号：US12303436

申请日：2007-06-07

申请人： Katsuaki Miyaji ,  Shunsuke Iwamoto ,  Yukihiro Shigeta ,  Yutaka Hirokawa ,  Shingo Oowada ,  Takanori Nakamura ,  Norihisa Ishiwata

发明人： Katsuaki Miyaji ,  Shunsuke Iwamoto ,  Yukihiro Shigeta ,  Yutaka Hirokawa ,  Shingo Oowada ,  Takanori Nakamura ,  Norihisa Ishiwata

IPC分类号： C07D403/12 ,  C07D401/12

CPC分类号： C07D231/22 ,  C07D401/12 ,  C07D403/12

摘要： Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided.A compound represented by the formula (I) (wherein R1, R2, R3, L1, L2, L3, X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

摘要翻译： 提供了有效预防，治疗或改善血小板生成素受体激活有效的疾病的化合物。 由式（I）表示的化合物或其溶剂化物，其中R1，R2，R3，L1，L2，L3，X和Y在说明书中定义），互变异构体，前药或药学上可接受的盐。

公开(公告)号：US08093251B2

公开(公告)日：2012-01-10

申请号：US12303436

申请日：2007-06-07

申请人： Katsuaki Miyaji ,  Shunsuke Iwamoto ,  Yukihiro Shigeta ,  Yutaka Hirokawa ,  Shingo Oowada ,  Takanori Nakamura ,  Norihisa Ishiwata

发明人： Katsuaki Miyaji ,  Shunsuke Iwamoto ,  Yukihiro Shigeta ,  Yutaka Hirokawa ,  Shingo Oowada ,  Takanori Nakamura ,  Norihisa Ishiwata

IPC分类号： C07D401/12 ,  C07D403/12 ,  A61K31/454 ,  A61K31/496 ,  A61P7/00

CPC分类号： C07D231/22 ,  C07D401/12 ,  C07D403/12

摘要： Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided.A compound represented by the formula (I) (wherein R1, R2, R3, L1, L2, L3, X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

摘要翻译： 提供了有效预防，治疗或改善血小板生成素受体激活有效的疾病的化合物。 由式（I）表示的化合物或其溶剂化物，其中R1，R2，R3，L1，L2，L3，X和Y在说明书中定义），互变异构体，前药或药学上可接受的盐。

公开(公告)号：US20100310537A1

公开(公告)日：2010-12-09

申请号：US12746507

申请日：2008-12-05

申请人： Takanori Nakamura ,  Atsushi Miyamura ,  Taito Nishino ,  Norihisa Ishiwata ,  Katsuaki Miyaji

发明人： Takanori Nakamura ,  Atsushi Miyamura ,  Taito Nishino ,  Norihisa Ishiwata ,  Katsuaki Miyaji

IPC分类号： A61K35/12 ,  C12N5/078 ,  A61P37/00 ,  A61P35/00 ,  A61P7/00 ,  A61P9/10 ,  A61P35/02

CPC分类号： C12N5/0647 ,  A61K35/12 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/999

摘要： An object of the present invention is to expand CD34+ cells ex vivo efficiently in a short term using a biologically safe and inexpensively obtainable low molecular weight compound. A still another object of the present invention is to provide an expansion agent for CD34+ cells useful for treatment of various hematopoietic disorders caused by dysfunctional hematopoietic stem cells and/or hematopoietic progenitor cells.A method for expanding CD34+ cells, which comprises culturing CD34+ cells ex vivo in the presence of a compound represented by the formula (I) (wherein A, B, L1, L2, L3, L4, R1, R2, R3, X and Y are defined in the description), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof.

公开(公告)号：US09115341B2

公开(公告)日：2015-08-25

申请号：US12746507

申请日：2008-12-05

申请人： Takanori Nakamura ,  Atsushi Miyamura ,  Taito Nishino ,  Norihisa Ishiwata ,  Katsuaki Miyaji

发明人： Takanori Nakamura ,  Atsushi Miyamura ,  Taito Nishino ,  Norihisa Ishiwata ,  Katsuaki Miyaji

IPC分类号： C12N5/00 ,  C12N5/0789 ,  C07D333/02 ,  C07D207/00 ,  A61K35/12

CPC分类号： C12N5/0647 ,  A61K35/12 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/999

摘要： An object of the present invention is to expand CD34+ cells ex vivo efficiently in a short term using a biologically safe and inexpensively obtainable low molecular weight compound. A still another object of the present invention is to provide an expansion agent for CD34+ cells useful for treatment of various hematopoietic disorders caused by dysfunctional hematopoietic stem cells and/or hematopoietic progenitor cells.A method for expanding CD34+ cells, which comprises culturing CD34+ cells ex vivo in the presence of a compound represented by the formula (I) (wherein A, B, L1, L2, L3, L4, R1, R2, R3, X and Y are defined in the description), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof.

摘要翻译： 本发明的目的是使用生物安全且廉价的低分子量化合物在短期内有效地扩增CD34 +细胞。 本发明的另一个目的是提供用于治疗由功能异常的造血干细胞和/或造血祖细胞引起的各种造血障碍的CD34 +细胞的扩张剂。 一种用于扩增CD34 +细胞的方法，其包括在式（I）表示的化合物（其中A，B，L1，L2，L3，L4，R1，R2，R3，X和Y）存在下离体培养CD34 +细胞 在描述中定义），化合物的互变异构体或药学上可接受的盐或其溶剂合物。